Rafael Pharmaceuticals’ Cancer Metabolism Drug Fails Phase III Assessment

Thursday morning provided a chilly announcement from Cranbury, New Jersey, as Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of cancer metabolism drug CPI-613® (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.